

77. The method of claim 58, wherein the Group I intron encoded endonuclease recognition site has been introduced by homologous or non-homologous recombination.

78. The method of claim 58, wherein the Group I intron encoded endonuclease recognition site has been introduced by retroviral infection.

79. The method of claim 78, wherein the retrovirus is generated with a vector selected from the group consisting of pMLV LTR SAPLZ, pG-MPL, pG-MtkPL, and pG-Mtk<sub>Δ</sub>PAPL.

80. The method of claim 58, wherein the transformation of the cell is performed by transfection, electroporation, microinjection, lipofection, or retroviral infection.

81. The method of claim 58, wherein the cell comprises a nucleotide sequence encoding the I-SceI enzyme. *E*

82. The method of claim 81, wherein the nucleotide sequence is in a plasmid.

83. The method of claim 82, wherein the plasmid is pRSV I-SceI or pCMV I-SceI.

84. The method of claim 63, wherein the Group I intron encoded endonuclease recognition site has been introduced by homologous or non-homologous recombination.

85. The method of claim 63, wherein the Group I intron encoded endonuclease recognition site has been introduced by retroviral infection.

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

86. The method of claim 85, wherein retrovirus is generated with a vector selected from the group consisting of pMLV LTR SAPLZ, pG-MPL, pG-MtkPL, and pG-Mtk<sub>Δ</sub>PAPL.

87. A method of culturing transgenic cells comprising

(a) providing a cell from a transgenic mouse, wherein said cell comprises a nucleotide sequence encoding a Group I intron encoded endonuclease; and

(b) culturing said cell under conditions that allow growth of said cell.

88. The method of claim 87, wherein said endonuclease is selected from the group consisting of Class I I-endonuclease, Class II I-endonuclease, Class III I-endonuclease, Class IV I-endonuclease, and Class V I-endonuclease.

89. The method of claim 88, wherein said endonuclease is a Class I I-endonuclease.

90. The method of claim 89, wherein said endonuclease is selected from the group consisting of I-SceI, I-SceIV, I-Csml, and I-PanI.

91. The method of claim 90, wherein said endonuclease is I-SceI.

92. The method of claim 87, wherein the nucleotide sequence is in a plasmid.

93. The method of claim 92, wherein the nucleotide sequence is pRSV I-SceI or pCMV I-SceI. --

**REMARKS**

Reconsideration of this application is respectfully requested. New claims 73-93 are derived from claims 23-47, canceled in applicants' December 4, 2000, Amendment,

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000